This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Lags Q3 Earnings Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Alkermes (ALKS) Q3 Earnings Match Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Oct 27, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, V, CNI, BA
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Gilead Sciences Stock Climb After Q3 Earnings?
by Shaun Pruitt
Big Pharma will close out this week's earnings reports, with Gilead Sciences (GILD) set to give its Q3 results on October 27. With GILD edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Company News for Oct 21, 2022
by Zacks Equity Research
Companies in The News Are: TSLA, T, ABB, MRNA, NVAX
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.
Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab
by Zacks Equity Research
Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Moderna (MRNA) Stock Moves -0.53%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $134, moving -0.53% from the previous trading session.
Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study
by Zacks Equity Research
Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.
Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK
by Zacks Equity Research
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids
by Sundeep Ganoria
Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
by Zacks Equity Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab
by Kinjel Shah
FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.
Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Albireo Pharma (ALBO) Soars 14.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland
by Zacks Equity Research
The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.